<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Efficacy of overnight leave-on sandwich therapy with 5% cysteamine and ectoine cream compared to hydroquinone 4% cream for treatment of melasma</dc:title><dc:creator>Kusumawardani,	Arie	(Avtor)
	</dc:creator><dc:creator>Murasmita,	Alamanda	(Avtor)
	</dc:creator><dc:creator>Rosmarwat,	Ervina	(Avtor)
	</dc:creator><dc:creator>Ashadi,	Lilik Norawati	(Avtor)
	</dc:creator><dc:creator>Setiawan,	Silvia V.	(Avtor)
	</dc:creator><dc:creator>Nikolovska,	Suzana	(Avtor)
	</dc:creator><dc:creator>Murlistyarini,	Sinta	(Avtor)
	</dc:creator><dc:creator>Wahyu Fitriyani,	Nurrahma	(Avtor)
	</dc:creator><dc:subject>cysteamine</dc:subject><dc:subject>hydroquinone</dc:subject><dc:subject>therapeutic</dc:subject><dc:subject>quality of life</dc:subject><dc:subject>melasma</dc:subject><dc:description>Introduction: Melasma is a common hypermelanosis presenting as dark patches on sun-exposed skin. Its treatment remains challenging due to slow response, especially in chronic cases. This study compares the efficacy of 5% cysteamine with ectoine cream versus 4% hydroquinone with ectoine cream in treating melasma. Methods: A double-blind randomized controlled trial was conducted from January to March 2024 across three centers in Indonesia: Dr. Moewardi Hospital (Surakarta), Gatot Soebroto Army Hospital (Jakarta), and Dr. Saiful Anwar Hospital (Malang). Participants were randomly assigned to Group A (5% cysteamine + ectoine) or Group B (4% hydroquinone + ectoine). Efficacy was evaluated using the modified Melasma Area and Severity Index (mMASI) and the JANUS-I skin analyzer. Quality of life was assessed using Melasma Quality of Life Scale (MELASQoL) and Dermatology Life Quality Index (DLQI) questionnaires. Results: Both groups demonstrated reduced mMASI and JANUS-I scores, with slightly greater improvement in Group A, although the difference was not statistically significant (p &gt; 0.05). Quality of living also improved in both groups, with no significant difference between them (p &gt; 0.05). Conclusions: Both treatment regimens effectively improved melasma pigmentation and QoL. Either 5% cysteamine with ectoine or 4% hydroquinone with ectoine can be considered viable treatment options for melasma.</dc:description><dc:date>2025</dc:date><dc:date>2026-06-09 08:37:58</dc:date><dc:type>Neznano</dc:type><dc:identifier>29901</dc:identifier><dc:identifier>UDK: 616.5:579</dc:identifier><dc:identifier>ISSN pri članku: 1318-4458</dc:identifier><dc:identifier>DOI: 10.15570/actaapa.2025.4</dc:identifier><dc:identifier>COBISS_ID: 260264451</dc:identifier><dc:language>sl</dc:language></metadata>
